BioSpace News Archive

Fate Therapeutics, Inc. announced that the Company will participate in the following upcoming investor conferences:

Travere Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Amgen will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 10,000 shares of common stock.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $.10 par value common stock of the company.

Nicox SA, an international ophthalmology company, announced a number of presentations at key ophthalmology conferences including the American Glaucoma Society Annual Meeting 2023 and the Association for Research in Vision and Ophthalmology Annual Meeting 2023.

ProKidney Corp. announced that Dr. Tim Bertram, Chief Executive Officer, will present at TD Cowen’s 43rd Annual Health Care Conference on Tuesday March 7, 2023 at 10:30 AM EST.

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 17 new employees.

SQI Diagnostics Inc. announced it is developing three diagnostic products based on University Health Network innovations and is exploring an initiative with Owlstone Medical and UHN on a fourth diagnostic product.